Intermediate/High Risk

1 of the following combinations:
* Gleason Score 7-10 + T1c-T2b + PSA < 50
* Gleason Score 6 + T2c-T4 + PSA < 50
* Gleason Score 6 + ≥ 50% positive biopsies + PSA < 50
* Gleason Score 6 + T1c-T2b + PSA > 20

RTOG 0924 - Phase III Randomized Trial of Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer

Castration-Resistant

* PSA doubling time < 10 months
* Ongoing ADT with GnRH or medical castration
* Testosterone < 50 ng/dL
* PSA ≥ 2 ng/mL
* No prior or present metastatic disease
* Asymptomatic prostate cancer

PROSPER – Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Schema Protocol Information - link to clinicaltrials.gov